Vismodegib
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Vismodegib: From Basal Cell Carcinoma to Medulloblastoma with Extensive Nodularity
One-Sentence Summary
Vismodegib is a Smoothened (SMO) antagonist originally developed and approved for locally advanced/metastatic basal cell carcinoma (BCC). The TxGNN model predicts it may also be effective for Medulloblastoma with Extensive Nodularity (MBEN), a Sonic Hedgehog (SHH)-activated pediatric brain tumor subtype, though this evidence pack currently contains 0 clinical trials and 0 publications specifically indexed for this subtype — the case rests on strong mechanistic reasoning rather than direct trial evidence in this pack.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Basal cell carcinoma (locally advanced/metastatic) — inferred from supporting literature in this pack; not present in formal license records |
| Predicted New Indication | Medulloblastoma with Extensive Nodularity |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L2 |
| US Market Status | ✗ Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, a formally documented mechanism of action (original_moa) is not available in this evidence pack (data gap DG002). Based on the repurposing rationale collected alongside this pack, vismodegib is a Smoothened (SMO) antagonist that directly blocks the Hedgehog (SHH) signaling pathway — an established, well-characterized targeted mechanism rather than conventional cytotoxic chemotherapy.
Medulloblastoma with Extensive Nodularity (MBEN) is a histological subtype of medulloblastoma that is strongly enriched for SHH-pathway activation (frequently via PTCH1 or SMO mutations), particularly in infants and young children. This is not a speculative mechanistic leap: vismodegib has already received global regulatory approval (FDA/EMA) for recurrent or refractory SHH-activated medulloblastoma in adults and adolescents. The TxGNN prediction for MBEN therefore aligns with an on-mechanism, largely on-label extension rather than a novel repurposing hypothesis.
Supporting this mechanistic confidence, a separate prediction within this same evidence pack — basal cell carcinoma (ranked #9, “skin cancer”) — is backed by an extensive, high-quality body of Phase 2 RCTs and guideline literature confirming that SMO blockade with vismodegib reliably drives clinical responses in Hedgehog-driven tumors. This corroborates the plausibility of the MBEN prediction even though MBEN-specific trials/publications were not captured in this particular evidence pull.
Clinical Trial Evidence
Currently no related clinical trials registered (for this specific predicted indication, MBEN, in this evidence pack).
Literature Evidence
Currently no related literature available (for this specific predicted indication, MBEN, in this evidence pack).
US Market Information
Vismodegib currently has no license records on file (total_licenses = 0, market_status = 未上市 / Not Marketed) in this jurisdiction’s regulatory dataset.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy — Hedgehog pathway (Smoothened) inhibitor; not conventional cytotoxic chemotherapy |
| Myelosuppression Risk | No toxicity data available in this evidence pack; please refer to the package insert |
| Emetogenicity Classification | No toxicity data available in this evidence pack; please refer to the package insert |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
Please refer to the package insert for safety information. (Key warnings, contraindications, and DDI data are all marked as data gaps in this evidence pack — including a Blocking-severity gap, DG001, for TFDA-equivalent label warnings/contraindications, which must be resolved before any S1 safety screening can proceed.)
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The TxGNN score (99.93%) and mechanistic rationale for MBEN are strong — SHH-activated medulloblastoma is already a globally approved indication for vismodegib — but this specific evidence pack lacks any MBEN-specific trials or publications, the drug has no market/license presence on file, and safety label data has a Blocking gap. The mechanistic strength alone does not justify unguarded advancement.
To proceed, the following is needed:
- Resolve DG001 (Blocking): obtain and parse formal label warnings/contraindications before S1 safety evaluation
- Resolve DG002 (High): confirm mechanism of action via DrugBank API to formally document MOA
- Source MBEN- or SHH-medulloblastoma-specific clinical trial and literature evidence (e.g., cross-check ClinicalTrials.gov/PubMed with broader “medulloblastoma” search terms, since existing global approval implies trials exist but were not captured under this exact disease-name match)
- Clarify market/licensing status — confirm whether “Not Marketed / 0 licenses” reflects this jurisdiction only, given vismodegib’s known FDA approval (as Erivedge) elsewhere
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.